Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MDS Nordion wins imaging supply deal with Molecular Insight:

This article was originally published in Clinica

Executive Summary

Radiotherapy company MDS Nordion has secured a six-year renewable contract to manufacture and supply Zemiva, a cardiac imaging agent, to Cambridge, Massachusetts-based Molecular Insight Pharmaceuticals. The product's first indication will be for the rapid diagnosis of cardiac ischaemia in acute care settings. Evidence suggests that Zemiva administered to patients at rest can detect ischaemia by imaging patients up to 30 hours after a cardiac event has occurred. It is estimated that 5-8 million patients in the US each year need to have determined whether their chest pain is caused by insufficient blood flow to the heart (a heart attack), according to Ottawa, Canada-based MDS.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel